熱門資訊> 正文
帕金森治疗早期数据公布后收益下滑
2024-08-29 20:33
- Gain Therapeutics (NASDAQ:GANX) fell ~12% premarket Thursday after the biotech posted initial data from a Phase 1 trial for its lead asset GT-02287 targeted at Parkinson’s disease.
- According to Gain (GANX), the study of 72 healthy volunteers indicated that single and multiple doses of GT-02287, including the highest planned dose levels, were safe and generally well tolerated across all age groups. The experimental therapy was found to be present in cerebrospinal fluid with peripheral target engagement.
- The company announced plans to begin a trial for GT-02287 in Parkinson’s disease patients by Q4 2024 and generate its data by mid-2025.
- “We are enthusiastic about the promising profile of GT-02287, particularly with the added observation of CNS exposure and target engagement,” interim CEO Gene Mack remarked.
More on Gain Therapeutics
- Gain Therapeutics, Inc. (GANX) Special Call Transcript
- Gain Therapeutics names Gene Mack as Interim CEO
- Gain Therapeutics shares slide on pricing public offering of units to raise $11M
- Seeking Alpha’s Quant Rating on Gain Therapeutics
- Historical earnings data for Gain Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
